UBS O'Connor’s Pyxis Oncology PYXS Stock Holding History

UBS O'Connor’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-146,400	Closed	-$228K	–	433
2024 Q4	$228K	Buy	+146,400	New	+$422K	0.01%	324

Other funds holding PYXS

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

UBS O'Connor's PYXS Position: Q1 2025 in Review

UBS O'Connor sold out of Pyxis Oncology (PYXS) in Q1 2025, closing a stake of 146,400 shares — an estimated $228K sold.

UBS O'Connor first reported a position in PYXS in Q4 2024 and held it in 1 quarter. The position peaked at $228K in Q4 2024. 88 funds tracked by Wall St. Rank hold PYXS as of Q1 2025.

UBS O'Connor reported no remaining Pyxis Oncology position as of Q1 2025 after selling out during the quarter.
UBS O'Connor sold 146,400 Pyxis Oncology shares in Q1 2025, an estimated $228K.
UBS O'Connor first reported a position in Pyxis Oncology in Q4 2024 and held it in 1 quarter.
UBS O'Connor's Pyxis Oncology position peaked at $228K in Q4 2024.
88 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.